A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1

ConclusionsIn patients with type 1 diabetes, treatment with BIL compared to GL for 26 weeks was associated with lower HbA1c, less nocturnal hypoglycemia, lower glucose variability, and weight loss. Increases in total and severe hypoglycemia, triglycerides, aminotransferases, and injection site reactions were also noted.Funded by Eli Lilly and Company. Registered at clinicaltrials.gov (NCT01481779).

Source: Diabetes, Obesity and Metabolism - July 7, 2016 Category: Endocrinology Authors: Satish Garg, Manfred Dreyer, Hideaki Jinnouchi, Jiani Mou, Yongming Qu, Mark L. Hartman, Myriam Rosilio, Scott J. Jacober, Edward J. Bastyr III, Tags: REVIEW ARTICLE Source Type: research